LOGIN  |  REGISTER
Astria Therapeutics

Veradigm Network Solution Practice Fusion EHR Receives Top Ranking

March 23, 2023 | Last Trade: US$4.65 0.05 -1.06

CHICAGO / Mar 23, 2023 / Business Wire / Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Allergy and Immunology and second for Rheumatology within its 2023 Ambulatory EHR by Physician Specialty category.

Practice Fusion, a Veradigm Network solution, is a cloud-based electronic health record (EHR) system designed specifically for independent practices, aiming to cater to the needs of medical professionals, service providers, and patients. It supports over 31,000 clinicians and helps drive better care for 5 million patients a month. Practice Fusion’s comprehensive system ensures secure and reliable access to all patient and practice information. The EHR is designed to streamline administrative tasks and provide clinicians with the tools they need to provide the best possible patient care. Practice Fusion's wide range of features, including clinical charting, lab and imaging integrations, and e-prescribing, helps practice staff save time and increase efficiency.

“Black Book’s survey highlights Veradigm’s commitment to providing independent practices with the support, cloud technology and cost-effective tools they need,” said Tom Langan, President and Chief Commercial Officer of Veradigm. “We are very proud of this honor from Black Book and are committed to empowering independent healthcare providers.”

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit http://www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube

© 2023 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page